Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FZ1Z
|
|||
| Former ID |
DIB014776
|
|||
| Drug Name |
Doxorubicin-CEA conjugate
|
|||
| Synonyms |
DOX-CEA; Doxorubicin-CEA conjugate, Immunomedics
Click to Show/Hide
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Terminated | [1] | |
| Company |
Immunomedics Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase II (TOP2) | Target Info | Modulator | [2] |
| Human Deoxyribonucleic acid (hDNA) | Target Info | Modulator | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007194) | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.